Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06309173Withdrawn

Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2

Role: lead

NCT06367751Not ApplicableActive Not Recruiting

Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)

Role: collaborator

NCT05009160Active Not Recruiting

DreaMS - Validation Study 1

Role: lead

NCT06526364Recruiting

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)

Role: collaborator

NCT04413032Not ApplicableCompleted

DreaMS - Digital Biomarkers for Multiple Sclerosis

Role: lead

All 5 trials loaded